Direct Thrombin Inhibitors in the Treatment of Immune-Mediated Heparin-Induced Thrombocytopenia

Heparin was first discovered in 1916 and at present is used in more than 12 million patients a year. In the 1950s, several physicians noticed an uncommon paradoxical phenomenon in which heparin appeared to function as a procoagulant instead of an anticoagulant. This phenomenon is now known as the immune-mediated heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS). Our understanding of this syndrome has evolved over the last 2 to 3 decades, and therapeutic options are arising. This article will focus on the most extensively studied therapy for HIT, which is the class of drugs known as the direct thrombin inhibitors. Specifically, we will focus on the mechanisms by which direct thrombin inhibitors may be useful in this syndrome, the evidence for their use, and the unique characteristics of the two FDA-approved agents in this class, lepirudin and argatroban.

Heparin-induced thrombocytopenia - HIT - direct thrombin inhibitors - argatroban - lepirudin

REFERENCES

• 1 Weismann R E, Tobin R W. Arterial embolism occurring during systemic heparin therapy.  Arch Surg. 1958;  76 219-227
• 2 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
• 3 Warkentin T, Greinacher A. Heparin-Induced Thrombocytopenia. New York; Marcel Dekker 2001
• 4 Williams R T, Damaraju L V, Mascelli M A et al.. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes.  Circulation. 2003;  107 2307-2312
• 5 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 502-507
• 6 King D J, Kelton J G. Heparin-associated thrombocytopenia.  Ann Intern Med. 1984;  100 535-540
• 7 Wallis D E, Workman D L, Lewis B E, Steen L, Pifarre R, Moran J F. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.  Am J Med. 1999;  106 629-635
• 8 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
• 9 Amiral J, Bridey F, Dreyfus M et al.. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.  Thromb Haemost. 1992;  68 95-96
• 10 Mitchell R, Cotran R. Hemodynamic disorders, thrombosis, and shock. In: Cotran R, Kumar V, Collins T Robbins Pathologic Basis of Disease. St. Louis, MO; WB Saunders 1999: 113-138
• 11 Bouchard B, Butenas S, Mann K, Tracy P. Interactions between platelets and the coagulation system. In: Michelson A Platelets. San Diego, CA; Academic Press 2002: 229-253
• 12 Hermann J P, Kutryk M J, Serruys P W. Clinical trials of direct thrombin inhibitors during invasive procedures.  Thromb Haemost. 1997;  78 367-376
• 13 Greinacher A, Volpel H, Janssens U et al.. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.  Circulation. 1999;  99 73-80
• 14 Greinacher A, Janssens U, Berg G et al.. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.  Circulation. 1999;  100 587-593
• 15 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
• 16 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
• 17 Lincoff A M, Bittl J A, Harrington R A et al.. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.  JAMA. 2003;  289 853-863
• 18 Campbell K R, Mahaffey K W, Lewis B E et al.. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.  J Invasive Cardiol. 2000;  12(suppl F) 14F-19F
• 19 Chamberlin J R, Lewis B, Leya F et al.. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog.  Can J Cardiol. 1995;  11 511-514
• 20 Reid III T, Alving B M. Hirulog therapy for heparin-associated thrombocytopenia and deep venous thrombosis.  Am J Hematol. 1994;  45 352-353
• 21 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.  Thromb Res. 2003;  110 73-82
• 22 Eichler P, Friesen H J, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.  Blood. 2000;  96 2373-2378
• 23 Huhle G, Hoffmann U, Song X, Wang L C, Heene D L, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.  Br J Haematol. 1999;  106 195-201
• 24 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.  Circulation. 2003;  108 2062-2065
• 25 Walenga J M, Ahmad S, Hoppensteadt D, Iqbal O, Hursting M J, Lewis B E. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.  Thromb Res. 2002;  105 401-405
• 26 Sheth S B, DiCicco R A, Hursting M J, Montague T, Jorkasky D K. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.  Thromb Haemost. 2001;  85 435-440
• 27 Anonymous . Argatroban for the treatment of heparin-induced thrombocytopenia.  The Medical Letter. 2001;  43 11-12
• 28 Schulman S, Wahlander K, Lundstrom T, Clason S B, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.  N Engl J Med. 2003;  349 1713-1721
• 29 Olsson S B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.  Lancet. 2003;  362 1691-1698
• 30 Wallentin L, Wilcox R G, Weaver W D et al.. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.  Lancet. 2003;  362 789-797